-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
Yantai Protgen Pharmaceutical
Yantai Protgen Pharmaceutical Technology Co., Ltd. was established in April 2015. Located in the Yantai Economic and Technological Development Zone, it is a wholly-owned subsidiary of Beijing Protgen Biotechnology Development Co., Ltd., and is an innovative, high-tech private enterprise.
Yantai Protgen Pharmaceutical Technology Co., Ltd. was established in April 2015. Located in the Yantai Economic and Technological Development Zone, it is a wholly-owned subsidiary of Beijing Protgen Biotechnology Development Co., Ltd., and is an innovative, high-tech private enterprise.
The company has completed the construction of Phase I of the Yantai Protgen Biopharmaceutical Park, covering 200 mu (approximately 33 acres) with a construction area of 120,000 square meters. Twelve single buildings, including production workshops, power centers, and quality inspection buildings, have been completed and put into use. The company strictly adheres to the concept of "quality originates from design." All factory buildings, equipment, and facilities are established according to the 2010 version of GMP standards. Major production and testing equipment is imported from countries such as the United States, France, Germany, Italy, and Sweden. Technical indicators have reached the international leading level, and the preparation process is economical, efficient, stable, and controllable.
Yantai Protgen Company is currently undertaking the industrialization implementation of the recombinant human serum albumin project. This project was initiated at the end of 2013, laboratory process development was completed in 2014, pilot-scale production was completed in 2015, animal testing was completed in 2018, and clinical trials were approved to commence in December 2020.
The injection-grade recombinant human serum albumin project represents the highest level of large-scale preparation technology for recombinant protein drugs today. The company is expected to be the first to complete clinical trials for the project and obtain a new drug certificate. Through the construction of a high-starting-point and high-level production platform, the company aims to achieve the industrialization goal of recombinant protein drugs. The company will safeguard lives with the power of science and technology, and return innovative results to society. It will create its own glorious chapter on the grand blueprint of a Healthy China and contribute Chinese wisdom and solutions to the realization of a global health dream.
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC